A French vaccine company has received €25 million in loans from the European Investment Bank to pay for pre-clinical trial research on a Zika vaccine.
The funds were awarded to Valneva SE, a pharmaceutical company, on 12 July during a signing ceremony in Paris. Earlier this year, Valneva announced it had developed a “highly purified” Zika vaccine candidate that is ready for testing in animals.
The loan was fast-tracked to allow vaccine trials to go ahead as soon as possible.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.